Preclinical assessment of ulixertinib, a novel ERK1/2 inhibitor

• Автори: Vinod Anera Balakrishna (Автор), Anitha Police (Автор), Rakesh Hiremath (Автор), Anusha Raj (Автор), Suresh P Sulochana (Автор), Devaraj V Chandrasekhar (Автор), Zainuddin Mohd (Автор), Ravi Kanth Bhamidipati (Автор), Ramesh Mullangi (Автор)
• Формат: Книга
• Опубліковано: International Association of Physical Chemists (IAPC), 2017-12-01T00:00:00Z.
• Предмети: article
• Онлайн доступ: Connect to this object online.

Ulixertinib (BVD-523) is a novel and selective reversible inhibitor of ERK1/ERK2. In xenograft studies it inhibited tumor growth in BRAF-mutant melanoma and colorectal xenografts as well as KRAS-mutant colorectal and pancreatic models. Ulixertinib is currently in Phase I clinical development for the...